Could a 14-Day pill reverse stomach precancer?
NCT ID NCT06590454
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug pyrvinium can reverse gastric intestinal metaplasia, a condition that raises the risk of stomach cancer. Thirty-two adults with high-risk features will take pyrvinium or a placebo for 14 days. Researchers will compare biopsies before and after treatment to see if the precancerous changes improve.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pyrvinium
- What this could lead to
- If it works, this could point toward a drug treatment to reverse precancerous changes in the stomach and lower the risk of stomach cancer.
- What could go wrong
- This is a small early-phase trial with only 32 people. The drug may not reverse the precancerous changes, and side effects are possible. Success in the lab may not translate to real-world benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC INTESTINAL METAPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke Health
RECRUITINGDurham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a traditional tablet turn back precancerous stomach changes?
- AI to predict cancer risk from gut bacteria and scans
- Can a common bile acid pill reverse stomach changes that lead to cancer?
- Can a common supplement reverse stomach cancer risk?
- New study aims to stop stomach cancer before it starts
- Turmeric compound tested to stop stomach cancer before it starts